Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 285-378-7 | CAS number: 85085-49-0 Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, etc., obtained from Mentha citrata, Labiatae.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity: Oral
The no observed Adverse Effect Level (NOAEL) for the test chemical Mentha citrata, ext for a duration of chronic toxicity study is considered to be 500 mg/Kg bw.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Remarks:
- experimental data of read across substances
- Justification for type of information:
- Data for the target chemical is summarized based on the structurally similar read across chemicals
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- according to guideline
- Guideline:
- other: Refer below principle
- Principles of method if other than guideline:
- WoE derived based on the experimental data from structurally and functionally similar read across chemicals
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Osborne-Mendel
- Details on species / strain selection:
- No data
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 1. TEST ANIMALS
- Source: No data available
- Age at study initiation: weanling rats
- Weight at study initiation: No data available
- Fasting period before study: No data available
- Housing: housed individually in wire cages
- Diet (e.g. ad libitum): food ad libitum
- Water (e.g. ad libitum): water ad libitum
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): No data available
- Humidity (%):No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): No data available
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: feed
- Details on route of administration:
- 1. No data
- Vehicle:
- other: Feed
- Details on oral exposure:
- 1. PREPARATION OF DOSING SOLUTIONS: The test chemical was mixed with feed at dose level of 0, 1000, 2500 or 10000 ppm (0, 100, 250 or 1000 mg/Kg/day).
DIET PREPARATION
- Rate of preparation of diet (frequency): Weekly
- Mixing appropriate amounts with (Type of food): Details not specified
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): Food
- Concentration in vehicle: 0, 1000, 2500 or 10000 ppm (0, 100, 250 or 1000 mg/Kg/day).
- Amount of vehicle (if gavage): No data available
- Lot/batch no. (if required): No data available
- Purity: No data available - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data
- Duration of treatment / exposure:
- 18 weeks
- Frequency of treatment:
- Daily
- Remarks:
- 0, 1000, 2500 or 10000 ppm (0, 100, 250 or 1000 mg/Kg/day).
- No. of animals per sex per dose:
- 1. Total: 80 (40 males and 40 females)
0 mg/Kg bw: 10/sex/dose
100 mg/Kg bw: 10/sex/dose
250 mg/Kg bw: 10/sex/dose
1000 mg/Kg bw: 10/sex/dose - Control animals:
- yes, concurrent vehicle
- Details on study design:
- 1. - Dose selection rationale: No data available
- Rationale for animal assignment (if not random): No data available
- Rationale for selecting satellite groups: No data available
- Post-exposure recovery period in satellite groups: No data available
- Section schedule rationale (if not random): No data available - Positive control:
- 1. No data
- Observations and examinations performed and frequency:
- 1. CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Weekly
- Cage side observations checked in table [No.?] were included. General condition
DETAILED CLINICAL OBSERVATIONS: No data
- Time schedule: No data
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes, weekly
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
- Time schedule for examinations:
OPHTHALMOSCOPIC EXAMINATION: No data
- Time schedule for examinations: No data
- Dose groups that were examined: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at termination
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: No data
- Parameters checked in table [No.?] were examined. White cell counts, red cell counts, haemoglobins and haematocrits.
CLINICAL CHEMISTRY: No data
- Time schedule for collection of blood: No data
- Animals fasted: No data
- How many animals: No data
- Parameters checked in table [No.?] were examined. No data
URINALYSIS: No data
- Time schedule for collection of urine: No data
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data - Parameters checked in table [No.?] were examined. No data
NEUROBEHAVIOURAL EXAMINATION: No data No data
- Time schedule for examinations:
- Dose groups that were examined:
- Battery of functions tested: sensory activity / grip strength / motor activity / other:
OTHER: No data - Sacrifice and pathology:
- 1. GROSS PATHOLOGY: Yes, The tissues of all the rats were examined macroscopically at the time of sacrifice. The viscera were removed and the liver, kidneys, spleen, heart, and testes were weighed.
HISTOPATHOLOGY: Yes, The viscera were removed and the liver, kidneys, spleen, heart, and testes were weighed. These organs, the remaining abdominal and thoracic viscera, and one hind leg, for bone, bone marrow, and muscle, were preserved in 10 % buffered formalin-saline solution for histopathological examination.
For routine histopathology, sections were embedded in paraffin wax and stained with haematoxylin and eosin - Other examinations:
- 1. No data
- Statistics:
- 1. No data
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not specified
- Description (incidence and severity):
- No macroscopic effects were noted in the 100 and 250 mg/Kg group
- Other effects:
- not specified
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects were noted at the mentioned dose level
- Critical effects observed:
- not specified
- Conclusions:
- The no observed Adverse Effect Level (NOAEL) for the test chemical Mentha citrata, ext for a duration of chronic toxicity study is considered to be 1000 mg/Kg bw.
- Executive summary:
Chronic and subacute toxicity studies were conducted to determine the toxic nature of Mentha citrata, ext upon repeated exposure by oral route. The studies are as mentioned below:
Chronic toxicity oral study for the test compound was studied in male and female Osborne-Mendel rats. The test compound was fed through the diet at a concentration of 0, 1000, 2500 or 10000 ppm (0, 100, 250 or 1000 mg/Kg bw) for 18 weeks. The animals were observed weekly for weight, food intake and general condition. Haematological examinations were made at termination. These examinations included white cell counts, red cell counts, haemoglobins and haematocrits. No effects were noted in the treated animals at the mentioned dose level. Based on the observations made, the no observed Adverse Effect Level (NOAEL) for the test compound in Osborne-Mendel rats is considered to be 1000 mg/Kg bw.
Another Repeated dose oral toxicity study was performed to determine the toxic nature of test chemical. The study was performed using female B6C3F1 mice.The test chemical was mixed with 1% methyl cellulose at dose levels of 0, 94, 188 or 375 mg/Kg/day. The dose for the main study were based on preliminary toxicity study. Test material was administered intragastrically on a daily basis for 5 days at 3 dose levels to B6C3F1 mice. During the study, the animals were observed for signs of toxicity, mortality and changes in body weight and organ weight. A host-resistance assay (Listeria monocytogenes bacterial challenge) was conducted to assess cell-mediate immunity. Humoral immunity was measured by the antibody Plaque-Forming cell (PFC) response to sheep erythrocytes. Cyclophosphamide served as an immunosuppressive positive control agent. No increase in the mortality or significant alteration to the Plaque-Forming cell response was noted. Hence the No Observed Adverse effect level (NOAEL) for female B6C3F1 mice is considered to be 375 mg/Kg/day.
In the same study, repeated dose oral toxicity study was performed to determine the toxic nature of test chemical. The study was performed using female B6C3F1 mice.The test chemical was mixed with corn oil at dose levels of 0, 750, 1500 or 3000 mg/Kg/day. The dose for the main study were based on preliminary toxicity study. Test material was administered intragastrically on a daily basis for 5 days at 3 dose levels to CD1 mice. During the study, the animals were observed for signs of toxicity, mortality and changes in body weight and organ weight. A host-resistance assay (Listeria monocytogenes bacterial challenge) was conducted to assess cell-mediate immunity. Humoral immunity was measured by the antibody Plaque-Forming cell (PFC) response to sheep erythrocytes. Cyclophosphamide served as an immunosuppressive positive control agent.Increased mortality following challenge with L. monocytogenes was noted at 750 mg/kg. The increased mortality observed following challenge with L. monocytogenes was not dose related and therefore considered to be incidental. Significant alteration to the Plaque-Forming cell response was not observed. Hence theNo Observed Adverse effect level (NOAEL) for female CD1 mice is considered to be 750 mg/Kg/day.
Based on the observations made, the no observed Adverse Effect Level (NOAEL) for the test chemical Mentha citrata, ext for a duration of chronic toxicity study is considered to be 1000 mg/Kg bw
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Data is from K2 publication
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity: Oral
Data available for the structurally and functionally similar read across chemicals have been reviewed to determine the toxic nature of Mentha citrata, ext (CAS no 85085 -49 -0). The studies are as mentioned below:
Chronic toxicity oral study for the test compound was studied in male and female Osborne-Mendel rats. The test compound was fed through the diet at a concentration of 0, 1000, 2500 or 10000 ppm (0, 100, 250 or 1000 mg/Kg bw) for 18 weeks. The animals were observed weekly for weight, food intake and general condition. Haematological examinations were made at termination. These examinations included white cell counts, red cell counts, haemoglobins and haematocrits. No effects were noted in the treated animals at the mentioned dose level. Based on the observations made, the no observed Adverse Effect Level (NOAEL) for the test compound in Osborne-Mendel rats is considered to be 500 mg/Kg bw.
Another Repeated dose oral toxicity study was performed to determine the toxic nature of test chemical. The study was performed using female B6C3F1 mice.The test chemical was mixed with 1% methyl cellulose at dose levels of 0, 94, 188 or 375 mg/Kg/day. The dose for the main study were based on preliminary toxicity study. Test material was administered intragastrically on a daily basis for 5 days at 3 dose levels to B6C3F1 mice. During the study, the animals were observed for signs of toxicity, mortality and changes in body weight and organ weight. A host-resistance assay (Listeria monocytogenes bacterial challenge) was conducted to assess cell-mediate immunity. Humoral immunity was measured by the antibody Plaque-Forming cell (PFC) response to sheep erythrocytes. Cyclophosphamide served as an immunosuppressive positive control agent. No increase in the mortality or significant alteration to the Plaque-Forming cell response was noted. Hence the No Observed Adverse effect level (NOAEL) for female B6C3F1 mice is considered to be 375 mg/Kg/day.
In the same study, repeated dose oral toxicity study was performed to determine the toxic nature of test chemical. The study was performed using female B6C3F1 mice.The test chemical was mixed with corn oil at dose levels of 0, 750, 1500 or 3000 mg/Kg/day. The dose for the main study were based on preliminary toxicity study. Test material was administered intragastrically on a daily basis for 5 days at 3 dose levels to CD1 mice. During the study, the animals were observed for signs of toxicity, mortality and changes in body weight and organ weight. A host-resistance assay (Listeria monocytogenes bacterial challenge) was conducted to assess cell-mediate immunity. Humoral immunity was measured by the antibody Plaque-Forming cell (PFC) response to sheep erythrocytes. Cyclophosphamide served as an immunosuppressive positive control agent.Increased mortality following challenge with L. monocytogenes was noted at 750 mg/kg. The increased mortality observed following challenge with L. monocytogenes was not dose related and therefore considered to be incidental. Significant alteration to the Plaque-Forming cell response was not observed. Hence theNo Observed Adverse effect level (NOAEL) for female CD1 mice is considered to be 750 mg/Kg/day.
Based on the observations made, the target chemical Mentha citrata, ext is not likely to be toxic as per the criteria mentioned in CLP regulation.
Justification for classification or non-classification
Based on the observations made, the target chemical Mentha citrata, ext (CAS no 85085 -49 -0) is not likely to be toxic as per the criteria mentioned in CLP regulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.